HeartSciences Inc Stock Price, News & Analysis

HeartSciences (NASDAQ: HSCS) has secured its first commercial customer, Westcliffe Health Innovations in the UK, for its MyoVista Insights™ platform. This cloud-native ECG management system is designed to be the first vendor- and device-agnostic platform capable of running AI-ECG algorithm models from multiple partners. The implementation will serve as a key reference site within the UK market, particularly for the National Health Service (NHS).

Westcliffe Health Innovations, led by Dr. Matthew Fay, provides cardiology services to the NHS in the Bradford and Leeds region. The partnership aims to enhance clinical decision-making and improve healthcare IT efficiency by streamlining ECG workflows and reducing operational costs. This milestone follows the recent launch of MyoVista Insights and its early adopter program earlier this month.

HeartSciences (Nasdaq: HSCS) announced that CEO Andrew Simpson will present at the Emerging Growth Conference 82 on Wednesday, May 21, 2025 at 10:15 AM EDT. The virtual presentation will include a live Q&A session, providing investors insight into the company's AI-ECG platform and mission.

HeartSciences specializes in AI-powered medical technology focused on transforming ECGs/EKGs for earlier heart disease detection. The presentation will highlight their AI-ECG platform, designed to enhance standard ECG diagnostic capabilities at the point of care. Simpson will also discuss a current Regulation A investment opportunity available to qualified investors.

HeartSciences (Nasdaq: HSCS) has announced an upcoming investor webinar scheduled for Wednesday, May 14, 2025, at 2:00 p.m. EDT. The event will feature CEO Andrew Simpson who will present and conduct a Q&A session focusing on the company's AI-powered ECG/EKG technology platform. The webinar will provide insights into HeartSciences' mission to transform early heart disease detection and its market opportunities. Simpson will also discuss a Regulation A investment opportunity available to qualified investors.

HeartSciences (NASDAQ: HSCS) has launched its MyoVista Insights™ platform, a cloud-native ECG Management System designed to enhance clinical decision-making and healthcare IT efficiency. The platform features vendor-agnostic integration capabilities for AI-ECG algorithms, a unique prioritization system, and standardized ECG reporting protocols.

Key features include patient-centric longitudinal comparisons, disease progression tracking, and enhanced workflow efficiency. Built on AWS technology stack, MyoVista Insights offers a pay-as-you-go model, reducing implementation and storage costs compared to legacy systems. The platform will integrate both company-developed and third-party AI-ECG algorithms in future releases to help identify patients requiring further cardiac testing earlier.

HeartSciences (HSCS) reported Q3 FY2025 financial results and business updates, highlighting significant progress in AI-powered ECG technology. The company reported no revenues for Q3 FY2025, with cash and cash equivalents of $2.6 million and shareholders' equity of $1.8 million as of January 31, 2025.

Key developments include:

• Final pre-submission meeting with FDA for MyoVista wavECG device in February 2025, with expected FDA clearance submission in H1 2025
• Successful completion of Phase 1 MyoVista Insights cloud-native platform in December 2024
• Pre-validation work completed with Rutgers for low ejection fraction algorithm
• CMS 2025 OPPS final rule inclusion enabling reimbursement upon commercial launch

The company's strategy focuses on modernizing ECG technology through AI-enhanced hardware and software solutions, positioning itself as the only company building next-gen ECG device hardware, device-agnostic cloud-native software, and AI-ECG algorithms.

HeartSciences (Nasdaq: HSCS), an AI-powered medical technology company focused on transforming ECGs/EKGs for earlier heart disease detection, has announced its engagement with Integrous Communications to enhance investor relations. The partnership aims to develop and execute a comprehensive investor communications program, leveraging Integrous' expertise in working with leading medical companies.

Andrew Simpson, Chairman and CEO, emphasized the importance of maintaining robust investor communications as the company continues its mission of transforming cardiovascular screening through AI-ECG technology. Mark Komonoski, Partner of Integrous Communications, expressed enthusiasm about partnering with HeartSciences to communicate its growth strategy and value proposition to the investment community.

HeartSciences (HSCS) reported Q2 FY2025 financial results and business updates. The company is developing next-generation ECG solutions, including the MyoVista® wavECG™ device and MyoVista® Insights™ cloud platform. Phase 1 of MyoVista Insights will be completed by end of 2024, with test site implementations planned for first half of 2025. FDA submission for MyoVista wavECG is expected around end of Q1 2025.

The company reported no revenue in Q2 FY2025, with cash and cash equivalents of $4.1 million and shareholders' equity of $4.0 million as of October 31, 2024. Their AI-ECG algorithms have been included in the CMS 2025 OPPS final rule, enabling reimbursement upon commercial launch.